Nanoemulsion applications in photodynamic therapy

Moghassemi, Saeid; Dadashzadeh, Arezoo; Azevedo, Ricardo Bentes; Amorim, Christiani Andrade

doi:10.1016/j.jconrel.2022.09.035

Cited by 41 publications

(25 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several NE-based drug formulations are in the pharmaceutical market, and many others are in various stages of clinical development. ( Kishore et al, 2022 ; Moghassemi et al, 2022 ).…”

Section: Lipid-based Nanoformulations For Cancer Treatment: Design Pr...mentioning

confidence: 99%

Lipid-engineered nanotherapeutics for cancer management

2023

View full text Add to dashboard Cite

Cancer causes significant mortality and morbidity worldwide, but existing pharmacological treatments are greatly limited by the inherent heterogeneity of cancer as a disease, as well as the unsatisfactory efficacy and specificity of therapeutic drugs. Biopharmaceutical barriers such as low permeability and poor water solubility, along with the absence of active targeting capabilities, often result in suboptimal clinical results. The difficulty of successfully reaching and destroying tumor cells is also often compounded with undesirable impacts on healthy tissue, including off-target effects and high toxicity, which further impair the ability to effectively manage the disease and optimize patient outcomes. However, in the last few decades, the development of nanotherapeutics has allowed for the use of rational design in order to maximize therapeutic success. Advances in the fabrication of nano-sized delivery systems, coupled with a variety of surface engineering strategies to promote customization, have resulted in promising approaches for targeted, site-specific drug delivery with fewer unwanted effects and better therapeutic efficacy. These nano systems have been able to overcome some of the challenges of conventional drug delivery related to pharmacokinetics, biodistribution, and target specificity. In particular, lipid-based nanosystems have been extensively explored due to their high biocompatibility, versatility, and adaptability. Lipid-based approaches to cancer treatment are varied and diverse, including liposomal therapeutics, lipidic nanoemulsions, solid lipid nanoparticles, nanostructured lipidic carriers, lipid-polymer nanohybrids, and supramolecular nanolipidic structures. This review aims to provide an overview of the use of diverse formulations of lipid-engineered nanotherapeutics for cancer and current challenges in the field, as researchers attempt to successfully translate these approaches from bench to clinic.

show abstract

“…Several NE-based drug formulations are in the pharmaceutical market, and many others are in various stages of clinical development. ( Kishore et al, 2022 ; Moghassemi et al, 2022 ).…”

Section: Lipid-based Nanoformulations For Cancer Treatment: Design Pr...mentioning

confidence: 99%

Lipid-engineered nanotherapeutics for cancer management

2023

View full text Add to dashboard Cite

show abstract

“…SVT-15473 was developed using a patented nanoemulsion technology, IMPACT-SVT® nanoemulsion (emulsion with nanometric-sized droplets), to improve drug–mucus penetration and bioadhesion, and to reduce irritation to the eye. 20 The trial involved 212 patients who had recently undergone cataract surgery from 22 hospitals in the United States. Recently, the company submitted a New Drug Application (NDA) to the FDA for approval with favorable results for this innovative nano-based delivery systems.…”

Section: Approved and Investigational Nano-based Drug Delivery Systemsmentioning

confidence: 99%

“…SVT-15473 was developed using a patented nanoemulsion technology, IMPACT-SVT® nanoemulsion (emulsion with nanometricsized droplets), to improve drug-mucus penetration and bioadhesion, and to reduce irritation to the eye. 20 Although nano-based drug delivery systems intended for topical instillation exhibit the ability to penetrate through the biological membrane and accumulate in the ocular tissues, few have received clinical use approval for the market. There are limited clinical trials that have been conducted for the clinical transition of topical instillation in the management of posterior segment diseases.…”

Section: Investigational Nano-based Drug Delivery Systemsmentioning

confidence: 99%

Nano-based ocular drug delivery systems: an insight into the preclinical/clinical studies and their potential in the treatment of posterior ocular diseases

Fan

Pang

2023

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

“…As a promising approach to cancer treatment, photodynamic therapy (PDT) has received significant attention in recent years ( Moghassemi et al , 2021a , 2022a , b ). Compared with the other common strategies for cancer therapy, PDT has fewer side effects, more selectivity, and can be specifically targeted toward the tumor site ( Lehmann, 2007 ; Chilakamarthi and Giribabu, 2017 ; Kwiatkowski et al , 2018 ; Moghassemi et al , 2021a ).…”

Section: Introductionmentioning

confidence: 99%

Ex vivopurging of cancer cells from ovarian tissue using photodynamic therapy: a novel strategy to restore fertility in leukemia patients

Moghassemi

Dadashzadeh

Camboni

et al. 2023

Human Reproduction Open

View full text Add to dashboard Cite

STUDY QUESTION Is it possible to purge leukemia cells from OT (OT) fragments before transplantation? SUMMARY ANSWER Our photodynamic therapy (PDT) approach has been shown to efficiently destroy leukemia cells from tumour-infiltration mimicking models (TIMs), indicating the feasibility of this technique to purge OT samples. WHAT IS KNOWN ALREADY Autotransplantation of cryopreserved OT is the most suitable option to preserve fertility for prepubertal girls and women who require immediate cancer treatment. Up to now, more than 200 live births have already been reported after OT cryopreservation and transplantation. Leukemia is the twelfth most common cancer in Europe among prepubertal girls and women of reproductive age and in 2020, the estimated number of new leukemia cases was higher than 33,000 in girls between 0 and 19 years old. Unfortunately, once their health has been restored, autotransplantation of cryopreserved OT for leukemia patients is not advised due to the high risk of transferring malignant cells back to the patient leading to leukemia recurrence. STUDY DESIGN, SIZE AND DURATION To safely transplant the OT from leukemia patients and restore their fertility, our goal was to develop a PDT strategy to eliminate leukemia ex vivo. To this end, we designed OR141-loaded niosomes (ORN) to create the most effective formulation for ex vivo purging OT fragments from acute myelogenous leukemia cells (n = 4). Moreover, to ensure that such treatments are not harmful to follicle survival and development so they can be deemed a potential fertility restoration alternative, the effect of the ORN-based PDT purging procedure on follicles was assessed after xenografting the photodynamic treated OT in SCID mice (n = 5). The work was carried out between September 2020 and April 2022 at the Catholic University of Louvain. PARTICIPANTS/MATERIALS, SETTING AND METHODS After establishing the best ORN formulation, our PDT approach was used to eradicate HL60 cells from ex vivo TIMs prepared by microinjection of cancer cell suspension in OT fragments. The purging efficiency was analyzed by droplet digital polymerase chain reaction and immunohistochemical analyses. Additionally, we evaluated the effect of ORN-based PDT on follicle density, survival and development and tissue quality in terms of fibrotic areas and vascularization after 7-day xenotransplantation to immunodeficient mice. MAIN RESULTS AND THE ROLE OF CHANCE The ex vivo purging of TIMs demonstrated that our PDT strategy could selectively eradicate the malignant cells from tissue fragments without affecting OT normal cells, as evidenced by PCR and immunohistochemical analysis. Regarding the effect of our PDT approach on follicle population and OT quality, our results after xenotransplantation revealed no significant difference between the follicle density of control (non-treated, grafted OT) and PDT-treated groups (2.38 ± 0.63 and 3.21 ± 1.94 morphologically normal follicles/mm2, respectively). In addition, our findings showed that the control and PDT-treated OT could be equally vascularized (7.65 ± 1.45% and 9.89 ± 2.21%, respectively). Similarly, the proportions of fibrotic area did not differ between the control (15.96 ± 5.94%) and PDT-treated groups (13.32 ± 3.05%). LARGE SCALE DATA N/A LIMITATIONS, REASONS FOR CAUTION This study did not use OT fragments from leukemia patients, but TIMs created after injection of HL60 cells in OT from healthy patients. Therefore, while the results are promising, whether our PDT approach will be equally successful in eliminating malignant cells from leukemia patients remains to be assessed. WIDER IMPLICATIONS OF THE FINDINGS Our results showed that the purging procedure causes no significant impairment effect on follicle development and tissue quality, suggesting that our novel PDT procedure could be a promising strategy to destroy leukemia cells in fragments of OT, allowing safe transplantation in cancer survivors. STUDY FUNDING/COMPETING INTEREST(S) This study was supported by grants from the Fonds National de la Recherche Scientifique de Belgique (FNRS-PDR Convention grant number T.0004.20 awarded to C.A.A.), Fondation Louvain (awarded to C.A.A.; a Ph.D. scholarship awarded to S.M., as part of a legacy from Mr. Frans Heyes, and a Ph.D. scholarship awarded to A.D. as part of a legacy from Mrs. Ilse Schirmer) and Foundation Against Cancer (grant 2018-042 awarded to A.C.). The authors declare no competing interests. WHAT DOES THIS MEAN FOR PATIENTS? Cancer treatment can damage ovarian function, potentially impairing patient fertility. In prepubertal girls and women who need cancer therapy immediately, it is possible to remove the ovarian tissue before the cancer treatment, cryopreserve it in cryobanks, and transplant it after cancer remission. However, this strategy cannot be offered to leukemia patients because of the high risk of reintroduction of cancer cells present in the cryopreserved ovarian tissue, which could potentially lead to leukemia recurrence. In order to safely transplant the ovarian tissue from these patients, these leukemia cells should be destroyed first. An alternative to selectively eradicate these cells without harming the follicle population could be photodynamic therapy. Based on this hypothesis, this study aimed to develop a novel photosensitizer to destroy leukemia cells in ovarian fragments. Our results showed that we could successfully purge these cells without harming follicle survival and development and ovarian tissue quality. This suggests that our novel procedure could be a promising strategy to destroy leukemia cells in ovary fragments, allowing their safe transplantation in cancer survivors.

show abstract

Nanoemulsion applications in photodynamic therapy

Cited by 41 publications

References 159 publications

Lipid-engineered nanotherapeutics for cancer management

Lipid-engineered nanotherapeutics for cancer management

Nano-based ocular drug delivery systems: an insight into the preclinical/clinical studies and their potential in the treatment of posterior ocular diseases

Ex vivopurging of cancer cells from ovarian tissue using photodynamic therapy: a novel strategy to restore fertility in leukemia patients

Contact Info

Product

Resources

About